CClinicalTrials.gg
Not yet recruitingNCT07075848Updated Jul 24, 2025

Outcomes of Delivery in Primigravida

An observational study in Vaginal Delivery, sponsored by Assiut University. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Sex
Female
01

Study summary

Primigravida women are a high-priority population due to their increased risk of obstetric interventions and adverse outcomes compared to multiparous women. Research indicates that first-time mothers account for a disproportionate number of emergency cesarean sections and instrumental deliveries, often due to factors such as inadequate labor support or failure to progress

Read the detailed description

The significance of auditing delivery care for primigravida women lies in their heightened vulnerability to complications such as prolonged labor, fetal distress, and higher rates of cesarean sections. Studies have shown that primigravida women often experience higher levels of fear and anxiety related to childbirth, which can influence their labor progression and overall birth experience. By systematically evaluating the care provided to this group, healthcare institutions can implement targeted interventions to enhance outcomes and patient satisfaction.

02

Conditions studied

  • Vaginal Delivery
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Primigravida come in labour

Inclusion criteria

  • Primigravida women admitted for delivery at the hospital
  • Singleton pregnancies.
  • Gestational age ≥ 28 weeks (to exclude preterm deliveries before viability).
  • Willingness to participate.

Exclusion criteria

Exclusion Criteria:

    • Multiparous women.

      • Multiple pregnancies.
      • Women who decline to participate.
      • Deliveries occurring outside the specified study period.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • study group

    Procedure: vaginal delivery

Interventions

  • Procedurevaginal delivery

    follow up of progress of labour

06

What researchers measure

Primary outcomes

  1. The rate of vaginal delivery in cases

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07075848
Lead sponsor
Assiut University
Responsible party
Salah Gobara (principal investigator, Assiut University) — Principal investigator
First posted
Jul 20, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jul 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion